

Resource Summary Report

Generated by [RRID](#) on Aug 27, 2026

HCT 15

RRID:CVCL_0292

Type: Cell Line

Proper Citation

RRID:CVCL_0292

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0292

Proper Citation: RRID:CVCL_0292

Description: Cell line HCT 15 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Colon adenocarcinoma

Defining Citation: [PMID:427742](#), [PMID:2041050](#), [PMID:7139607](#), [PMID:7247963](#), [PMID:7621404](#), [PMID:7972006](#), [PMID:8197130](#), [PMID:8464898](#), [PMID:9000147](#), [PMID:9000572](#), [PMID:9331090](#), [PMID:9809040](#), [PMID:10700174](#), [PMID:10737795](#), [PMID:11314036](#), [PMID:11414198](#), [PMID:11416159](#), [PMID:11526487](#), [PMID:11668190](#), [PMID:12584437](#), [PMID:15748285](#), [PMID:15900046](#), [PMID:16854228](#), [PMID:17088437](#), [PMID:18167186](#), [PMID:19372543](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20570890](#), [PMID:20606684](#), [PMID:22068913](#), [PMID:22336246](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22628656](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24042735](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:24755471](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25926053](#), [PMID:25944804](#), [PMID:26169745](#), [PMID:26537799](#), [PMID:26589293](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27807467](#), [PMID:28179481](#), [PMID:28192450](#), [PMID:28196595](#), [PMID:28683746](#), [PMID:28854368](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31733513](#), [PMID:31978347](#), [PMID:35839778](#), [PMID:38861359](#)

Comments: Population: Caucasian., Part of: RAS genetic alteration cell panel (ATCC TCP-1031)., Part of: PI3K genetic alteration cell panel (ATCC TCP-1028)., Part of: NCI-60 cancer cell line panel., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCT 15

Synonyms: HCT-15, HCT.15, HCT15

Cross References: BTO:BTO_0002201, CLO:CLO_0003666, EFO:EFO_0002188, MCCL:MCC:0000182, CLDB:cl1576, CLDB:cl4985, ABM:T8966, AddexBio:C0009010/381, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CCL-225, BCRC:60539, BioGRID_ORCS_Cell_line:868, BioSample:SAMN01821556, BioSample:SAMN01821630, BioSample:SAMN03471553, BioSample:SAMN10987770, cancercellines:CVCL_0292, CCRID:1101HUM-PUMC000247, CCRID:3101HUMTCHu133, CCRID:4201HUM-CCTCC00250, CCTCC:GDC0250, Cell_Model_Passport:SIDM00789, ChEMBL-Cells:ChEMBL3307945, ChEMBL-Targets:ChEMBL612263, CLS:300229, ColonAtlas:HCT15, Cosmic:711261, Cosmic:873700, Cosmic:875902, Cosmic:887222, Cosmic:897458, Cosmic:905007, Cosmic:905937, Cosmic:913889, Cosmic:934567, Cosmic:947354, Cosmic:995403, Cosmic:1044258, Cosmic:1057756, Cosmic:1066206, Cosmic:1092601, Cosmic:1122324, Cosmic:1132569, Cosmic:1175841, Cosmic:1184092, Cosmic:1187307, Cosmic:1218878, Cosmic:1305354, Cosmic:1310950, Cosmic:1312338, Cosmic:1436020, Cosmic:1466814, Cosmic:1479592, Cosmic:1526922, Cosmic:1609492, Cosmic:1676747, Cosmic:1708403, Cosmic:1995438, Cosmic:1998443, Cosmic:2036655, Cosmic:2156942, Cosmic:2301979, Cosmic:2664053, Cosmic:2727470, Cosmic:2760066, Cosmic:2800585, Cosmic:2811051, Cosmic-CLP:905937, DepMap:ACH-000997, DSMZ:ACC-357, DSMZCellDive:ACC-357, ECACC:91030712, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:905937, GEO:GSM2129, GEO:GSM50189, GEO:GSM50253, GEO:GSM206502, GEO:GSM274763, GEO:GSM274764, GEO:GSM481406, GEO:GSM513816, GEO:GSM514293, GEO:GSM741257, GEO:GSM743444, GEO:GSM750792, GEO:GSM784011, GEO:GSM799332, GEO:GSM799395, GEO:GSM844554, GEO:GSM846356, GEO:GSM887063, GEO:GSM888133, GEO:GSM1153402, GEO:GSM1178151, GEO:GSM1178152, GEO:GSM1178153, GEO:GSM1181251, GEO:GSM1181363, GEO:GSM1346875, GEO:GSM1374519, GEO:GSM1374520, GEO:GSM1374521, GEO:GSM1374522, GEO:GSM1448178, GEO:GSM1669869, GEO:GSM2124665, GEO:GSM2550002, IARC_TP53:21114, ICLC:HTL00001, IGRhCellID:HCT15, KCB:KCB 2011097YJ, KCLB:10225, LiGeA:CCLE_761, LINCS_LDP:LCL-1178, Lonza:492, MetaboLights:MTBLS227, NCI-DTP:HCT-15, PharmacDB:HCT15_518_2019, PRIDE:PXD003539, PRIDE:PXD005235, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL_0292, PubChem_Cell_line:CVCL_0292, RCB:RCB1958, SKY/M-FISH/CGH:2786, TKG:TKG 0504, TOKU-E:1423, Wikidata:Q54882006

ID: CVCL_0292

Hierarchy: cvcl_3449

Record Creation Time: 20220427T220321+0000

Record Last Update: 20260815T233712+0000

Ratings and Alerts

No rating or validation information has been found for HCT 15.

Warning: Discontinued: RCB; RCB1958

Population: Caucasian., Part of: RAS genetic alteration cell panel (ATCC TCP-1031)., Part of: PI3K genetic alteration cell panel (ATCC TCP-1028)., Part of: NCI-60 cancer cell line panel., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 950 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Wang B, et al. (2026) MYLK4 promotes colorectal cancer progression by regulating lipid metabolism reprogramming via targeting ferroptosis. *Neoplasia* (New York, N.Y.), 73, 101270.

Kamgar M, et al. (2026) Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma. *Cancer research*, 86(8), 2042.

Yokomura M, et al. (2026) Afatinib exerts an inhibitory effect on T cell-mediated cytotoxicity. *Cancer immunology, immunotherapy : CII*, 75(1), 33.

Chantzoura E, et al. (2026) The Allogeneic FAP-CAR-IL15 iNKT Therapy MiNK-215 Remodels the Tumor Stroma to Enhance Antitumor Immunity. *Cancer immunology research*, 14(2), 243.

Watlington WK, et al. (2026) Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation. *Molecular oncology*.

Takano K, et al. (2026) DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity. *Molecular cancer therapeutics*, 25(1), 7.

Zhuang X, et al. (2026) Receptor-ubiquitination-targeting antibody-drug conjugates for enhanced endocytosis and lysosomal delivery. *Cell chemical biology*, 33(4), 506.

Lentz RW, et al. (2026) Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer model. *Frontiers in oncology*, 16, 1721685.

- Baars B, et al. (2026) RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors. *Molecular cancer research : MCR*, 24(1), 60.
- Yue Z, et al. (2026) Subcellular Redistribution of Endomembrane GPR15 Promotes NAD⁺-Mediated Metabolic Reprogramming and Boosts 5-FU Chemosensitivity in Colorectal Cancer. *Cancer research*, 86(9), 2253.
- Duan X, et al. (2026) DDR1 Promotes Immune Evasion in Colorectal Cancer by Orchestrating IL33-Mediated M2-like Polarization of Tumor-Associated Macrophages. *Cancer immunology research*, 14(6), 900.
- Dong Z, et al. (2026) Molecular Mechanism of NSUN6-Mediated Epigenetic Modifications in the Malignant Progression of Colorectal Cancer Cells. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 40(10), e71883.
- Xiao X, et al. (2026) Single-Mitochondrion ATP Profiling Directs Discovery of Targetable OXPHOS Dependency in Cancers. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(21), e13341.
- Hosogane M, et al. (2026) Variant-specific interaction of kinectin 1 with the multi-tRNA synthetase complex regulates ER sheet organization. *iScience*, 29(1), 114303.
- Ebata Y, et al. (2026) Proteasome inhibitor, ixazomib prevents topoisomerase-I degradation and reverses irinotecan resistance in colorectal cancer. *Molecular oncology*.
- Choi PH, et al. (2026) Distinct ERK and PI3K dependencies mediate a heterogeneous response to RAS(ON) inhibition in KRAS-mutant colorectal cancer. *Cell reports*, 45(7), 117559.
- Zhan W, et al. (2026) Cathepsin-D-mediated MHC class I degradation contributes to immune evasion in colorectal cancer. *Cell reports. Medicine*, 102534.
- Huang M, et al. (2026) KRT81 promotes metastasis of colorectal cancer by acting as a protein scaffold for ezrin. *Oncogene*, 45(3), 459.
- Lee CJ, et al. (2026) The dysadherin/carbonic anhydrase 9 axis shapes an acidic tumor microenvironment to promote colorectal cancer progression. *Signal transduction and targeted therapy*, 11(1), 19.
- Cheng H, et al. (2026) Cholesterol Reprograms Oxysterol Metabolism via the LOX1/CH25H/CYP7B1 Signaling Axis to Drive Multidrug Resistance in Colorectal Cancer. *Human mutation*, 2026, 3675889.